87 results
6-K
EX-99.2
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
.
The COMP positive opinion is supported by efficacy and safety data from three Phase 3 studies in acromegaly patients including the pivotal MPOWERED Phase
6-K
EX-99.5
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
), that examined the efficacy and safety of Filsuvez® (birch bark extract) gel/Oleogel-S10 versus vehicle control gel in EB. Filsuvez® is approved in the EU … with dressing changes
Filsuvez® was well tolerated, with a similar safety profile to control gel
Professor Dedee Murrell, Head of Dept. of Dermatology, St
6-K
EX-99.2
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
and safety study of Oleogel-S10 (birch triterpenes) in patients with inherited EB, followed by a 24-month open-label single-arm phase. Analyses … in wound burden with a continued reassuring safety profile
Dr Tracy Cunningham, Chief Medical Officer of Amryt, commented: “We are pleased to present new
6-K
EX-99.5
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
-term safety and efficacy data for Mycapssa® from the second year of the OPTIMAL open label extension study in acromegaly patients
Mycapssa® new patent
6-K
EX-99.2
AMYT
Amryt Pharma Plc
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
p.m. - 2:30 p.m. EST
Poster Presentation
Title: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open
6-K
EX-99.3
or7gkrygjmj
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
6-K
EX-99.1
qkhcirrkfix1k
23 Jun 22
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
7:26am
424B4
xwq43aa
20 May 22
Prospectus supplement with pricing info
5:06pm
424B4
dgo28surg svuffe
20 May 22
Prospectus supplement with pricing info
4:58pm
424B4
i9cahvm
20 May 22
Prospectus supplement with pricing info
4:57pm
F-3
gm3uwk8 79
11 May 22
Shelf registration (foreign)
5:22pm
POS AM
g3znoqt s6l
11 May 22
Prospectus update (post-effective amendment)
5:20pm
POS AM
fmdf8ru87l eah
11 May 22
Prospectus update (post-effective amendment)
5:19pm
6-K
EX-99.4
6j8 szlc9cx
11 May 22
Current report (foreign)
4:30pm
6-K
EX-99.3
u7iuze4tjf
11 May 22
Current report (foreign)
4:30pm
424B3
2w6q0hll3py7roa5vmhn
4 May 22
Prospectus supplement
8:35am
424B3
r2so67
4 May 22
Prospectus supplement
7:45am
6-K
EX-99.1
huvv8tc
4 May 22
Amryt Reports Record Q1 2022 Results
7:43am